- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02757560
Dietary Lipid Induced Insulin Resistance
Mechanisms of Dietary Lipid Induced Insulin Resistance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the first aim, investigators will test whether a short-term high SFA-diet induces and increases insulin resistance in participants with normal and abnormal glucose tolerance, respectively, and determine the associated changes in muscle, adipose tissue and inflammatory cell composition, pathway activation and insulin signaling. Investigators will identify changes in specific signal pathways within these tissues and cells that are hypothesized to mediate or modulate insulin action. Primary mechanisms and pathways examined will include local tissue and systemic inflammation, formation of bioactive lipid intermediates, generation of endoplasmic reticulum (ER) stress, and mitochondrial dysfunction/reactive oxygen formation. By performing studies in participants with normal glucose tolerance and in those with abnormal glucose tolerance investigators will also determine whether the extent and mechanisms of insulin resistance vary with initial degrees of glucose intolerance.
In the second aim, to determine if the extent and mechanisms of insulin resistance vary with dietary composition, investigators will determine whether diets of similar caloric content as the SFA-diet, but enriched in monounsaturated fatty acids or carbohydrates, also induce insulin resistance and whether similar or different mechanistic pathways are responsible. Identifying similarities and differences between diets in inflammatory cell and tissue changes and comparing their relationships with peripheral and tissue insulin action will further clarify which cell and tissue events are most closely linked to development of insulin resistance.
In the final aim, to identify the temporal sequence of mechanistic pathways for insulin resistance and the role of cell and tissue cross-talk in these events, investigators will evaluate inflammatory cell, skeletal muscle and adipose tissue composition and pathway changes after acute, subacute, and more chronic dietary challenges in the same individuals. This will also permit assessment of whether repeated dietary challenges create changes in tissues that resemble those found in more chronic and advanced states of insulin resistance.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Carl T. Hayden VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index (BMI) from 25-35 kg/m2
- normal glucose tolerance (NGT) diagnosis based on fasting glucose value 100mg/dl and 2 hr glucose <140 mg/dl after a standard 75 gm glucose load; impaired fasting glucose (IFG) on fasting glucose value ≥100 and <126 mg/dl and 2 hr glucose <140 mg/dl; impaired glucose tolerance (IGT) based on 2 hr glucose ≥140 and <200 mg/dl and a fasting glucose <126 mg/dl
- Fasting triglyceride levels <500 mg/dl
Exclusion Criteria:
- Type 1 or 2 diabetes mellitus or a hemoglobin A1c value ≥ 6.5 mg/dl
- Any diabetes medications in the past month, thiazolidinedione medications in the prior 3 months or prior regular use of insulin
- Use of diets, medications (e.g., steroids, weight loss medications ) or current or planned behavior changes (e.g. acute weight loss, exercise training) that will influence changes in IR
- Creatinine >2.0 mg/dl or other laboratory evidence of significant active disease, including hepatic enzyme elevation >2x normal and anemia, known "Nonalcoholic Fatty Liver Disease", bleeding risk
- Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems, or recent history of nausea or vomiting
- Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks
- Cardiovascular event, stable or unstable angina or other major illness in the past 6 months
- Current regular use of anti-inflammatory medications (e.g. salicylates > 1 gm/ day) or antioxidants in excess of a daily multi-vitamin, including supplements (e.g. fish oils)
- Lipid lowering medications must be at a stable dose for at least 2 months prior to participation
- Ethanol consumption more than 4 oz day; more than occasional smoker
- Reproductively active women not on contraceptives
- Known allergies, prior reactions or contraindications to proposed clinical agents (e.g Octreotide)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SFA versus control diet
Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet.
For the control diet participants will follow a dietary plan for 72 hours prior to testing.
For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack.
On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control).
Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
|
SFA versus control diet
|
Experimental: MUFA versus control diet
Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet.
For the control diet participants will follow a dietary plan for 72 hours prior to testing.
For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack.
On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control).
Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
|
MUFA versus control diet
|
Experimental: CARB versus control diet
Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet.
For the control diet participants will follow a dietary plan for 72 hours prior to testing.
For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack.
On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control).
Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
|
CARB versus control diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steady-state plasma glucose (SSPG)
Time Frame: 150-180 min
|
Average plasma glucose concentrations during min 150-180 of the insulin suppression test (IST)
|
150-180 min
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acylcarnitine species
Time Frame: Overnight fast, 3-hour post breakfast
|
Measured by chromatography electrospray ionization mass spectrometry on plasma and skeletal muscle samples.
|
Overnight fast, 3-hour post breakfast
|
Diacylglycerol species
Time Frame: Overnight fast, 3-hour post breakfast
|
Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.
|
Overnight fast, 3-hour post breakfast
|
Ceramides species
Time Frame: Overnight fast, 3-hour post breakfast
|
Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.
|
Overnight fast, 3-hour post breakfast
|
Insulin signaling proteins
Time Frame: Overnight fast, 3-hour post breakfast
|
Measured on skeletal muscle and subcutaneous adipose tissue samples.
|
Overnight fast, 3-hour post breakfast
|
Inflammation markers
Time Frame: Overnight fast, 3-hour post breakfast
|
Cytokines and adipokines will be measured in plasma after the diet treatments by ELISA techniques.
Mononuclear cells inflammatory gene expression will be measured by real time polymerase chain reaction (RT-PCR).
Inflammation will be measured in muscle and adipose tissue by RT-PCR and Western blood analysis.
|
Overnight fast, 3-hour post breakfast
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter D Reaven, MD, Phoenix Veterans Affairs Health Care System
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 029
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
Paloma Almeda-ValdésCompleted
-
German Diabetes CenterYale UniversityRecruiting
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Assiut UniversityCompleted
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
-
The University of Texas Medical Branch, GalvestonCompletedInsulin Resistance, DiabetesUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
Clinical Trials on SFA diet
-
Maastricht University Medical CenterUnilever R&DCompletedObesity | Diet, Healthy | Fatty Liver, NonalcoholicNetherlands
-
University of SurreyImperial College London; University of ReadingCompletedHealthy | Lipid Metabolism | LipidsUnited Kingdom
-
University of ReadingCompleted
-
Rutgers, The State University of New JerseyCompleted
-
University of OsloThe Research Council of Norway; University of OxfordCompleted
-
Uppsala UniversitySwedish Council for Working Life and Social ResearchCompletedObesity | Diabetes | Fatty Liver | Insulin ResistanceSweden
-
Consorcio Centro de Investigación Biomédica en...Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de BellvitgeCompletedPulmonary DiseaseSpain, Germany, Greece, Italy, Netherlands, United Kingdom
-
Penn State UniversityHass Avocado BoardCompletedCardiovascular Disease | HyperlipidemiaUnited States
-
Ludwig-Maximilians - University of MunichCompleted
-
University Hospital, EssenUnknownPeripheral Arterial Disease | Claudication, IntermittentGermany